Immunology and inflammation biotech Alumis has demonstrated its lead drug candidate can hit a certain validated target to treat plaque psoriasis. Now the company has $250 million for pivotal tests that could show whether this small molecule keeps up with a competitive field that includes pharmaceutical giants going after this same target..

免疫学和炎症生物技术公司Alumis已经证明其主要候选药物可以达到治疗斑块状银屑病的特定有效靶点。现在，该公司有2.5亿美元用于关键测试，以显示这种小分子是否能跟上竞争领域的步伐，其中包括追求同一目标的制药巨头。。

Alumis joined the public markets Friday after pricing its offering of about 13.12 million shares at $16 each, raising $210 million. In preliminary IPO terms set earlier this week, South San Francisco-based Alumis projected offering more than 17.6 million shares in the range of $16 to $18 each, which would have raised $300 million at the pricing midpoint.

Alumis于周五加入公开市场，此前其发行约1312万股股票的定价为每股16美元，筹资2.1亿美元。在本周早些时候确定的初步IPO条款中，总部位于南旧金山的Alumis预计将发行1760多万股，每股价格在16美元至18美元之间，这将在定价中点筹集到3亿美元。

Alumis is making up some of that by selling 2.5 million shares at the IPO price to one of its largest investors. This concurrent private placement brings Alumis an additional $40 million. Shares of Alumis now trade on the Nasdaq under the stock symbol “ALMS.”.

Alumis通过以IPO价格向其最大的投资者之一出售250万股，弥补了其中的一些不足。同时进行的私募为Alumis带来了额外的4000万美元。Alumis的股票目前在纳斯达克交易，股票代码为“ALMS”。

Alumis is developing drugs that address TYK2, an enzyme that plays a role in signaling pathways involved in inflammation. In 2022, Bristol Myers Squibb’s Sotyktu became the first FDA-approved TYK2 inhibitor with moderate-to-severe plaque psoriasis as its first indication. Now other companies are trying to show that they can also drug this target, but in ways that offer advantages in safety, efficacy, or both.

Alumis正在开发针对TYK2的药物，TYK2是一种在炎症信号通路中起作用的酶。2022年，百时美施贵宝（Bristol-Myers Squibb）的Sotyktu成为美国食品和药物管理局（FDA）批准的第一种TYK2抑制剂，其首次适应症为中度至重度斑块状牛皮癣。现在，其他公司正试图证明他们也可以对这一目标进行药物治疗，但在安全性、有效性或两者兼有方面都有优势。

Takeda Pharmaceutical has reached late-stage testing with its TYK2-blocking drug candidate. In the IPO filing, Alumis contends the BMS and Takeda TYK2 inhibitors have not shown the ability to achieve complete inhibition of the target enzyme, limiting their therapeutic potential. In clinical testing of the Takeda drug, skin rashes were observed in higher doses.

武田制药（Takeda Pharmaceutical）的TYK2阻断候选药物已进入后期测试阶段。在IPO申请中，Alumis认为BMS和武田TYK2抑制剂没有显示出完全抑制靶酶的能力，从而限制了它们的治疗潜力。在武田药物的临床试验中，观察到较高剂量的皮疹。

By contrast, Alumis describes ESK-001 as a next-generation TYK2 inhibitor..

相比之下，Alumis将ESK-001描述为下一代TYK2抑制剂。。

Payers

付款人

How Payers Use Tech to Support Healthcare Transformation

付款人如何利用技术支持医疗保健转型

Executives at the ViVE Payer Insights event earlier this year discussed prior authorization, AI, value-based care and the role of tech to help achieve their goals.

今年早些时候，ViVE Payer Insights活动的高管们讨论了事先授权、人工智能、基于价值的护理以及技术在帮助实现目标中的作用。

“We believe that ESK-001 may potentially overcome the limitations of first-generation allosteric TYK2 inhibitors by achieving maximal target inhibition without causing dose limiting safety or tolerability issues,” Alumis said in the IPO filing. “We believe this will result from optimized physicochemical properties, favorable and highly predictable [pharmacokinetics], and lack of significant drug interactions.”.

Alumis在首次公开募股文件中表示：“我们认为ESK-001可能通过实现最大的靶向抑制而不引起剂量限制性安全性或耐受性问题，从而克服第一代变构TYK2抑制剂的局限性。”。“我们相信这将是由于优化的理化性质，有利且高度可预测的[药代动力学]，以及缺乏显着的药物相互作用。”。

There are other companies developing next-generation TYK2 inhibitors, though some have dropped out due to uncompetitive data. Alumis expects to begin two Phase 3 tests of ESK-001 in plaque psoriasis in the second half of this year. The drug is also in mid-stage testing in systemic lupus erythematosus.

还有其他公司正在开发下一代TYK2抑制剂，尽管由于缺乏竞争力的数据，一些公司已经退出。Alumis预计在今年下半年开始两项ESK-001斑块型银屑病的3期试验。该药物还在系统性红斑狼疮的中期测试中。

Alumis said in the IPO filing it expects to report results from this study in 2026..

Alumis在IPO申请中表示，预计将于2026年报告这项研究的结果。。

ESK-001 was acquired from FronThera. Alumis said that with learnings from this lead program, it developed a second program, A-005. While this drug is also a TYK2 inhibitor, its ability to penetrate into the central nervous system offers the potential to address neuroinflammatory and neurodegenerative diseases, such as multiple sclerosis.

ESK-001是从FronThera获得的。Alumis说，从这个领先项目中吸取了教训，它开发了第二个项目a-005。虽然这种药物也是一种TYK2抑制剂，但其穿透中枢神经系统的能力为解决神经炎症和神经退行性疾病（如多发性硬化症）提供了潜力。

A Phase 1 test of A-005 in healthy volunteers began in April. Alumis expects to report preliminary results by the end of this year..

A-005在健康志愿者中的第一阶段测试于4月开始。Alumis预计将在今年年底报告初步结果。。

Alumis formed in 2021 and was incubated by Foresite Labs, the startup incubator of venture capital firm Foresite Capital. The company was initially named Esker Therapeutics. When the startup closed its $200 million Series B financing in 2022, it also announced the name change.

Alumis成立于2021年，由风险投资公司Forestite capital的创业孵化器Forestite Labs孵化。该公司最初被命名为Esker Therapeutics。当这家初创公司在2022年关闭了2亿美元的B系列融资时，它也宣布了更名。

Sponsored Post

赞助帖子

Physician Targeting Using Real-time Data: How PurpleLab’s Alerts Can Help

使用实时数据确定医生目标：PurpleLab的警报如何帮助

By leveraging real-time data that offers unprecedented insights into physician behavior and patient outcomes, companies can gain a competitive advantage with prescribers. PurpleLab®, a healthcare analytics platform with one of the largest medical and pharmaceutical claims databases in the United States, recently announced the launch of Alerts which translates complex information into actionable insights, empowering companies to identify the right physicians to target, determine the most effective marketing strategies and ultimately improve patient care.

通过利用实时数据，为医生行为和患者结果提供前所未有的见解，公司可以获得与处方者的竞争优势。PurpleLab®是一个医疗保健分析平台，拥有美国最大的医疗和药品索赔数据库之一，最近宣布推出警报，将复杂信息转化为可行的见解，使公司能够确定合适的医生，确定最有效的营销策略，并最终改善患者护理。

.

.

By PurpleLab

PurpleLab

“Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words ‘allumer’ — French for illuminate — and ‘immunis’ — Latin for the immune system,” the company said in the IPO fling.

该公司在首次公开募股活动中表示：“我们的名字Alumis体现了我们启发免疫学的使命，它的灵感来自法语中“allumer”表示照明，拉丁语中“immunis”表示免疫系统。”。

Prior to the IPO, Alumis had raised $459.1 million in equity financing. Its most recent financing was a $259 million Series C round in March. Foresite Capital is Alumis’s largest shareholder, followed by AyurMaya Capital Management, according to the prospectus. AyurMaya is the investor buying shares in the private placement.

在IPO之前，Alumis已经筹集了4.591亿美元的股权融资。其最近一次融资是3月份的2.59亿美元C轮融资。根据招股说明书，Foresite Capital是Alumis的最大股东，其次是AyurMaya Capital Management。AyurMaya是购买私募股权的投资者。

As of the end of March, Alumis reported a cash position of $133.7 million. Together with the new capital, the company plans to spend $345 million to bring lead program ESK-001 through a topline data readout in its Phase 3 plaque psoriasis and through the completion of Phase 2b testing in lupus. Another $5 million is earmarked for Phase 1 testing of A-005..

截至3月底，Alumis报告的现金头寸为1.337亿美元。与新资本一起，该公司计划花费3.45亿美元，通过其3期斑块状牛皮癣的topline数据读数和完成狼疮2b期测试，推出领先项目ESK-001。另外500万美元专门用于A-005的第一阶段测试。。

Photo: Getty Images

照片：盖蒂图片

Topics

主题

Alumis

底部

biopharma nl

生物制药

biotech IPO

生物技术IPO

Clinical Trials

临床试验

immunology

免疫学

inflammation

炎症

South San Francisco

南旧金山

MedCity News Daily Newsletter

MedCity新闻每日通讯

Sign up and get the latest news in your inbox.

注册并在收件箱中获取最新消息。

Enter your email address

输入您的电子邮件地址

Subscribe Now

立即订阅

We will never sell or share your information without your consent. See our privacy policy.

未经您同意，我们绝不出售或共享您的信息。请参阅我们的隐私政策。